


# Validation of a Jacobian AI-based Method to Measure Cerebellar Volume Changes in Multiple System Atrophy

B. De Blasi<sup>1</sup>, K. Kinnunen<sup>1</sup>, M. Papoutsis<sup>1</sup>, R. Joules<sup>1</sup>, I. Qureshi<sup>2</sup>, R. Wolz<sup>1,3</sup>, for the M-STAR Study Investigators  
<sup>1</sup>IXICO plc, London UK; <sup>2</sup>Biohaven Pharmaceuticals, Connecticut USA; <sup>3</sup>Imperial College London, London UK

**Cerebellar atrophy**, seen in neurodegenerative diseases, such as multiple system atrophy (MSA), can be quantified as cerebellar volume change on magnetic resonance imaging. The estimation of cerebellar volume change, in an accurate, robust, consistent and scalable manner would be highly beneficial for clinical trials in multiple system atrophy (MSA) [1-3].

This work performs the **validation of a fully automatic volume change workflow in MSA using the Jacobian integration** from non-linear warp fields estimated with a convolutional neural network (CNN)-based 3D T1-weighted (T1W) image analysis workflow.

We analysed an MSA dataset (N=191, M-STAR clinical trial), consisting of individuals with predominant parkinsonism (MSA-P, N=76) or predominant cerebellar features (MSA-C, N=115). We did not differentiate between placebo and treatment groups. Each participant dataset comprised baseline and week 48 T1W scans, which were pre-processed cross-sectionally and pair-wise longitudinally. **Baseline images were segmented with a multi-atlas parcellation method to generate cerebellar ROIs** [4].



We trained a CNN to perform non-linear registration of a serial, affinely aligned, pre-processed image pairs [5]. This provides a voxel-wise, high-resolution warp field in a fraction of the computed time taken by traditional methods [6].

Volume change measures were obtained through the integration of Jacobian determinants from the deformation fields within the baseline cerebellum segmentations (mean log Jacobian).


We compared cerebellar volume change from the proposed Jacobian CNN method and a temporally coupled segmentation-based method (ATLAS) [7].

Both methods used multi-ATLAS based cerebellum baseline segmentations [4].

The Jacobian CNN method reported higher group differences based on annualised cerebellar volume change from baseline. Of note, a negative (positive) sign indicates atrophy (growth).

Method	MSA-P Mean (SE)*	MSA-C Mean (SE)*	MSA-C vs MSA-P difference Mean (SE)*	P-value	Cohen's d Effect size
CNN	-1.75% (0.14)	-2.33% (0.11)	-0.57% (0.18)	0.001	-0.47
ATLAS	0.34% (0.16)	0.04% (0.13)	-0.30% (0.21)	0.151	-0.21

\* Adjusted for age, gender, total UMSARS at Screening



**Reduced sample sizes and increased effect size** (for pooled MSA sub-types) were obtained with the proposed Jacobian CNN method when compared to both the ATLAS method and the PROMESA (Progression Rate Of MSA under EGCG Supplementation as Anti-Aggregation Approach) study, which used a widely used software, SPM12 [8].

Method	Mean (SD) Annualized % Change from Baseline	N	Cohen's d Effect Size	Sample size per arm*
CNN	-2.11% (1.29)	191	-1.63	94
ATLAS	0.16% (1.41)	191	0.11	20846.8
PROMESA (Placebo Group only)	-3.4% (3.70)	8	-0.92	297.4

\* For hypothetical 2-arm clinical trial with 80% power, 25% treatment effect, 0.05 alpha

The developed framework provides a **fully automatic solution for estimating cerebellar volume change with increased sensitivity over comparable methods**. This framework is **flexible and highly scalable**, and as such has the potential to be advantageous for future clinical trials.

## References:

- [1] Hara D., Maki F., Tanaka S., Sasaki R., Hasegawa Y., "MRI-based cerebellar volume measurements correlate with the Internal Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration", *Cerebellum & Ataxias*, 2016, 14, doi:10.1186/s40673-016-0052-4
- [2] Faber J., Schaprian T., Berkan K., Reetz K., Franca M.C., de Rezende T.J.R., Hong J., et al., "Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3", *Movement Disorders*, 2021, 36(10), 2273-2281, doi:10.1002/mds.28610
- [3] Paviour D.C., Price S.L., Jahanshahi M., Lees A.J., Fox N.C., "Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy", *Brain*, 2006, 129(4), 1040-1049, doi:10.1093/brain/aw021
- [4] Wolz R., Aljabar P., Hajnal J.V., Hammers A., Rueckert D., et al., "LEAP: learning embeddings for atlas propagation", *NeuroImage*, 2010, 49(4), 1316-1325, doi:10.1016/j.neuroimage.2009.09.069
- [5] Reinwald M., Joules R., Papoutsis M., Weatheritt J., Wolz R., "Towards a fully automatic AI framework to calculate voxel-wise atrophy in the human brain", *Alzheimer's & Dementia*, 2021, 17(Suppl. 5), doi:10.1002/alz.050068
- [6] Avants B.B., Tustison N.J., Song G., Cook P.A., Klein A., Gee J.C., "A reproducible evaluation of ANTs similarity metric performance in brain image registration", *NeuroImage*, 2011, 54(3), 2033-2044, doi:10.1016/j.neuroimage.2010.09.025
- [7] Wolz R., Heckmann R.A., Aljabar P., Hajnal J.V., Hammers A., Lotjonen J., Rueckert D., et al., "Measurement of hippocampal atrophy using 4D graph-cut segmentation: Application to ADNI", *NeuroImage*, 2010, 52(1), 109-118, doi:10.1016/j.neuroimage.2010.04.006
- [8] Levin J., Maab S., Schubert M., Giese A., Oertel W.H., Poewe W., Trenkwalder C., "Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial", *The Lancet Neurology*, 2019, 18(8), 724-735, doi:10.1016/S1474-4422(19)30141-3